CTOR Citius Oncology Inc.

Price (delayed)

$0.7905

Market cap

$73.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$74.67M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 18

Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIRâ„¢ ...

Highlights
The company's gross profit rose by 42% QoQ
The revenue rose by 42% since the previous quarter
The net income has dropped by 80% since the previous quarter and by 64% year-on-year
Citius Oncology's quick ratio has plunged by 76% from the previous quarter

Key stats

What are the main financial stats of CTOR

CTOR stock price

How has the Citius Oncology stock price performed over time
Intraday
1.41%
1 week
-2%
1 month
-14.08%
1 year
-15.75%
YTD
-20.95%
QTD
27.52%

Financial performance

How have Citius Oncology's revenue and profit performed over time
Revenue
$5.61M
Gross profit
$4.49M
Operating income
-$43.52M
Net income
-$42.51M
Gross margin
80.1%
Net margin
-757.6%
The company's operating income has shrunk by 94% QoQ and by 73% YoY
The net income has dropped by 80% since the previous quarter and by 64% year-on-year
The company's gross profit rose by 42% QoQ
The revenue rose by 42% since the previous quarter

Price vs fundamentals

How does CTOR's price correlate with its fundamentals

Growth

What is Citius Oncology's growth rate over time

Valuation

What is Citius Oncology stock price valuation
P/E
N/A
P/B
1.98
P/S
14.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.31
The EPS has plunged by 52% from the previous quarter and by 27% YoY
The P/B is 51% below the last 4 quarters average of 4.0
The company's equity fell by 40% QoQ
The revenue rose by 42% since the previous quarter

Efficiency

How efficient is Citius Oncology business performance
Citius Oncology's ROIC has plunged by 89% from the previous quarter and by 42% YoY
CTOR's ROE has shrunk by 80% QoQ and by 34% YoY
The ROA has plunged by 76% from the previous quarter and by 28% YoY
The ROS has contracted by 31% from the previous quarter

Dividends

What is CTOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTOR.

Financial health

How did Citius Oncology financials performed over time
The total assets is 54% greater than the total liabilities
Citius Oncology's quick ratio has plunged by 76% from the previous quarter
The current ratio is down by 40% from the previous quarter but it is up by 39% YoY
The debt is 89% less than the equity
The company's debt to equity has surged by 57% QoQ
The company's equity fell by 40% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.